📜二甲胺,2-Chloro-N-(5-Cyclopropyl-1H-Pyrazol-3-yl)Pyrimidin-4-Amine,N,N-二异丙基乙胺置于(6-Fluoro-14(2-(Trimethylsilyl)Ethoxy)Methyl)-1H-Pyrrolo[3,2-B]Pyridin-5-Yl,Sio2,Methanol-Dichloromethane,N4-(5-Cyclopropyl-1H-Pyrazol-3-yl)-N2-((6-Fluoro-14(2-(Trimethylsilyl)Ethoxy)Methyl)-1H-Pyrrolo[3,2-B]Pyridin-5-yl)Methyl体系中,用 2,4-二甲基-3-戊醇 用作溶剂,化学反应 15.0H,以to Afford 40 Mg (30%) Of N4-(5-Cyclopropyl-1H-Pyrazol-3-yl)-N2-((6-Fluoro-14(2-(Trimethylsilyl)Ethoxy)Methyl)-1H-Pyrrolo[3,2-B]Pyridin-5-yl)Methyl)-N2-Methylpyrimidine-2,4-Diamine As A Brown Oil (40 Mg,30%)的收率获得n-(4-氨基嘧啶-2-基)甲胺
参考文献:Serine/threonine Kinase Inhibitors
标题:Serine/threonine Kinase Inhibitors
摘要:具有以下式子i的化合物,其中a,R1A,R1B,R2,R3,R4,R5,R6,R7,R8,Ra,Rb,X1,X2,X3和n的定义如本文所述,是pak1的抑制剂.还公开了用于治疗癌症和增殖性疾病的组合物和方法.